(Journal Article): Is a New Immune Response Mediator in the NF-κB pathway - SUMO-4 - Related to Type 1 Diabetes?
 
Sia C (Department of Immunology, United Biomedical Inc., 25 Davids Drive, Hauppage, New York 11788, USA., csia(at)unitedbiomedical.com )
 
IN: Rev Diabetic Stud 2005; 2(2):58-60
Impact Factor(s) of Rev Diabetic Stud: 0.125 (2006)

Fulltext:    HTML  PDF

ABSTRACT: Type 1 diabetes mellitus (T1DM) is hallmarked by a complete loss of insulin secretion capacity caused by T cell-mediated destruction of pancreatic β-cells [1, 2]. The disorder has a complex pathogenesis involving genetic and environmental factors, it appears impossible hitherto to explain sufficiently how islet abnormalities arise and which mechanisms trigger immune cells to become diabetogenic.

TYPE OF PUBLICATION: Review

REFERENCES:

1. Kay TW, Thomas HE, Harrison LC, Allison J. The beta cell in autoimmune diabetes: many mechanisms and pathways of loss. Trends Endocrinol Metab 2000. 11(1):11-15. [DOD]
2. Kurrer MO, Pakala SV, Hanson HL, Katz JD. Beta cell apoptosis in T cell-mediated autoimmune diabetes. Proc Natl Acad Sci U S A 1997. 94(1):213-218. [DOD]
3. Daniel D, Gill RG, Schloot N, Wegmann D. Epitope speci-ficity, cytokine production profile and diabetogenic activity of insulin-specific T cell clones isolated from NOD mice. Eur J Immunol 1995. 25(4):1056-1062. [DOD]
4. Rabinovitch A. An update on cytokines in the pathogenesis of insulin-dependent diabetes mellitus. Diabetes Metab Rev 1998. 14:129-151. [DOD]
5. Ghosh S, May MJ, Kopp EB. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998. 16:225-260. [DOD]
6. Cardozo AK, Heimberg H, Heremans Y, Leeman R, Kutlu B, Kruhoffer M, Orntoft T, Eizirik DL. A compre-hensive analysis of cytokine-induced and nuclear factor-kappa B-dependent genes in primary rat pancreatic beta-cells. J Biol Chem 2001. 276(52):48879-48886. [DOD]
7. Hayashi T, Faustman D. NOD mice are defective in protea-some production and activation of NF-kappaB. Mol Cell Biol 1999. 19(12):8646-8659. [DOD]
8. Eizirik DL, Mandrup-Poulsen T. A choice of death - the signal-transduction of immune-mediated beta-cell apoptosis. Diabetologia 2001. 44(12):2115-2133. [DOD]
9. Gylvin T, Bergholdt R, Nerup J, Pociot F. Characterization of a nuclear-factor-kappa B (NFkappaB) genetic marker in type 1 diabetes (T1DM) families. Genes Immun 2002. 3(7):430-432. [DOD]
10. Hegazy DM, O'Reilly DA, Yang BM, Hodgkinson AD, Millward BA, Demaine AG. NFkappaB polymorphisms and susceptibility to type 1 diabetes. Genes Immun 2001. 2(6):304-308. [DOD]
11. Lgssiar A, Hassan M, Schott-Ohly P, Friesen N, Nicoletti F, Trepicchio WL, Gleichmann H. Interleukin-11 inhibits NF-kappaB and AP-1 activation in islets and prevents diabetes induced with streptozotocin in mice. Exp Biol Med (Maywood) 2004. 229(5):425-436. [DOD]
12. Mabley JG, Hasko G, Liaudet L, Soriano F, Southan GJ, Salzman AL, Szabo C. NFkappaB1 (p50)-deficient mice are not susceptible to multiple low-dose streptozotocin-induced diabetes. J Endocrinol 2002. 173(3):457-464. [DOD]
13. Matunis MJ, Pickart CM. Beginning at the end with SUMO. Nat Struct Mol Biol 2005. 12(7):565-566. [DOD]
14. Seeler JS, Dejean A. Nuclear and unclear functions of SU-MO. Nat Rev Mol Cell Biol 2003. 4(9):690-699. [DOD]
15. Muller S, et al. SUMO: a regulator of gene expression and genome integrity. Oncogene 2004. 23(11):1998-2008. [DOD]
16. Guo D, Li M, Zhang Y, Yang P, Eckenrode S, Hopkins D, Zheng W, Purohit S, Podolsky RH, Muir A, et al. A functional variant of SUMO4, a new I kappa B alpha modifier, is associated with type 1 diabetes. Nat Genet 2004. 36(8):837-841. [DOD]
17. Li M, Guo D, Isales CM, Eizirik DL, Atkinson M, She JX, Wang CY. SUMO wrestling with type 1 diabetes. J Mol Med 2005. 83(7):504-513. [DOD]
18. Kosoy R, Concannon P. Functional variants in SUMO4, TAB2, and NFkappaB and the risk of type 1 diabetes. Genes Immun 2005. 6(3):231-235. [DOD]
19. Bohren KM, Nadkarni V, Song JH, Gabbay KH, Owerbach D. A M55V polymorphism in a novel SUMO gene (SUMO-4) differentially activates heat shock transcription fac-tors and is associated with susceptibility to type I diabetes mel-litus. J Biol Chem 2004. 279(26):27233-27238. [DOD]
20. He H, Soncin F, Grammatikakis N, Li Y, Siganou A, Gong J, Brown SA, Kingston RE, Calderwood SK. Ele-vated expression of heat shock factor (HSF) 2A stimulates HSF1-induced transcription during stress. J Biol Chem 2003. 278(37):35465-35475. [DOD]
21. Alastalo TP, Hellesuo M, Sandqvist A, Hietakangas V, Kallio M, Sistonen L. Formation of nuclear stress granules involves HSF2 and coincides with the nucleolar localization of Hsp70. J Cell Sci 2003. 116:3557-3570. [DOD]
22. Smyth DJ, Howson JM, Lowe CE, Walker NM, Lam AC, Nutland S, Hutchings J, Tuomilehto-Wolf E, Tuomilehto J, Guja C, et al. Assessing the validity of the association be-tween the SUMO4 M55V variant and risk of type 1 diabetes. Nat Genet 2005. 37(2):110-111. [DOD]
23. Qu H, Bharaj B, Liu XQ, Curtis JA, Newhook LA, Paterson AD, Hudson TJ, Polychronakos C. Assessing the validity of the association between the SUMO4 M55V variant and risk of type 1 diabetes. Nat Genet 2005. 37(2):111-112. [DOD]
24. Park Y, Park S, Kang J, et al. Additional support for a ge-netic association between SUMO4 and type 1 diabetes in the Korean population. Nat Genet (in press). [DOD]
25. Wang CY, Yang P, She JX. Genetic heterogeneity of the IDDM5 (SUMO4) locus. Nat Genet (in press). [DOD]